Empire-CF study: A phase 2 clinical trial of leukotriene A4 hydrolase inhibitor acebilustat in adult subjects with cystic fibrosis is a research paper published in Journal of Cystic Fibrosis (2021). On theSindex it has a DataRank of 0.464. It has been cited 21 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.464
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →National Institutes of Health
Grant: P30DK072482
National Institutes of Health
Grant: UL1TR002548
National Institutes of Health
Grant: UL1TR003096
National Institute for Health Research
Grant: 2P30DK072482-12
UAB CF Research and Translation Core Center
National Institute for Health Research
Grant: UL1TR003096-01
NHLBI NIH HHS
Grant: R35 HL135816
National Institutes of Health
Grant: 3UL1TR002548-03S1
Clinical and Translational Science Collaborative of Cleveland
National Institutes of Health
Grant: 3UL1TR003096-02S3
Center for Clinical and Translational Science
National Institute for Health Research (NIHR)
Cystic Fibrosis Foundation
FWCI
1.57
Citation Percentile
0.8%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals